Usefulness of bicarbonate-based Impella purge solution in a patient with heparin-induced thrombocytopenia: the first case report of long-term management in Japan.
Bicarbonate-based purge solution
Heart failure
Heparin-induced thrombocytopenia
Impella
Off-label use
Thrombosis
Journal
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs
ISSN: 1619-0904
Titre abrégé: J Artif Organs
Pays: Japan
ID NLM: 9815648
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
received:
28
12
2023
accepted:
12
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
Percutaneous mechanical circulatory support utilizing micro-axial flow pumps, such as the Impella group of devices, has become a life-saving technique in the treatment of refractory cardiogenic shock, with ever-increasing success rates. A 30-year-old man presented with acute decompensated heart failure and a severely reduced left ventricular ejection fraction (17%). Despite initial treatment with inotropic drugs and intra-aortic balloon pump support, his hemodynamic status remained unstable. Transition to Impella CP mechanical circulatory support was made on day 6 owing to persistently low systolic blood pressure. A significant decline in platelet count prompted suspicion of heparin-induced thrombocytopenia (HIT), later confirmed by positive platelet-activated anti-platelet factor 4/heparin antibody and a 4Ts score of 6 points. Argatroban was initially used as the purge solution, but owing to complications, a switch to Impella 5.0 and a bicarbonate-based purge solution (BBPS) was performed. Despite additional veno-arterial extracorporeal membrane oxygenation support on day 24, the patient, aiming for ventricular assist device treatment and heart transplantation, died from infection and multiple organ failure. Remarkably, the Impella CP continued functioning normally until the patient's demise, indicating stable Impella pump performance using BBPS. This case highlights the usefulness of BBPS as an alternative to conventional Impella heparin purge solution when HIT occurs.
Identifiants
pubmed: 38839668
doi: 10.1007/s10047-024-01452-0
pii: 10.1007/s10047-024-01452-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Vandenbriele C, et al. Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock: JACC review topic of the week. J Am Coll Cardiol. 2022;79:1949–62.
doi: 10.1016/j.jacc.2022.02.052
pubmed: 35550692
Al-Ayoubi AM, et al. Use of sodium bicarbonate purge solution in Impella devices for heparin-induced thrombocytopenia. J Pharm Pract. 2023;36:1035–8.
doi: 10.1177/08971900221089078
pubmed: 35388725
Sigala MI, et al. A case series analysis of bicarbonate-based purge solution administration via Impella ventricular assist device. Am J Health Syst Pharm. 2024;81:e115–21.
doi: 10.1093/ajhp/zxad278
pubmed: 37952169
Amin AP, et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020;141:273–84.
doi: 10.1161/CIRCULATIONAHA.119.044007
pubmed: 31735078
Reed BN, et al. Survey of anticoagulation practices with the Impella percutaneous ventricular assist device at high-volume centers. J Interv Cardiol. 2019;2019:3791307.
doi: 10.1155/2019/3791307
pubmed: 31772529
pmcid: 6739784
Beavers CJ, et al. Optimizing anticoagulation for patients receiving Impella support. Pharmacotherapy. 2021;41:932–42.
doi: 10.1002/phar.2629
pubmed: 34597429
Beavers CJ, Dunn SP, DiDomenico RJ, Moretz J, Jennings DL. Bicarbonate-based purge solution during Impella support: a growing alternative. J Am Coll Cardiol. 2022;79:633.
doi: 10.1016/S0735-1097(22)01624-2
Abiomed. Heparin-Free Purge Solution. https://www.heartrecovery.com/education/heparin-free-purge . Accessed 17 Apr 2024
El-Hennawy AS, Frolova E, Romney WA. Sodium bicarbonate catheter lock solution reduces hemodialysis catheter loss due to catheter-related thrombosis and blood stream infection: an open-label clinical trial. Nephrol Dial Transplant. 2019;34:1739–45.
doi: 10.1093/ndt/gfy388
pubmed: 30668833
pmcid: 6775472
Simonsen KA, et al. Use of a novel bicarbonate-based Impella 5.5 purge solution in a coagulopathic patient. J Card Surg. 2021;36:4773–5. https://doi.org/10.1111/jocs.16008 .
doi: 10.1111/jocs.16008
pubmed: 34562278
Gilman V, Popovsky M, McMinn S (2021) Bicarbonate as an alternative to heparin in Impella purge fluid: understanding the biochemical basis. Paper presented at: ASAIO 66th Annual Conference, Washington DC, 10–12 2021
Van Edom C, Van Puyvelde T, Jacobs S, Vandenbriele C. Switch to a bicarbonate-based Impella CP purge solution in a patient with haemothorax: a case report. Eur Heart J Case Rep. 2023. https://doi.org/10.1093/ehjcr/ytad022 .
doi: 10.1093/ehjcr/ytad022
pubmed: 36727126
pmcid: 9883732
Dietrich JN, Kazmi H. Bleeding risks in patients on percutaneous ventricular assist devices receiving two different dextrose concentrations of heparinized purge solution: a case series. J Pharm Pract. 2019;32:464–9.
doi: 10.1177/0897190018757148
pubmed: 29439593
Oishi H, et al. Increased risk of purge system malfunction after Impella 5.0 replacement: a case series. J Artif Organs. 2023;26:79–83. https://doi.org/10.1007/s10047-022-01337-0 .
doi: 10.1007/s10047-022-01337-0
pubmed: 35575950
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759–65.
doi: 10.1111/j.1538-7836.2006.01787.x
pubmed: 16634744
Kondo T, et al. Comparison of Impella 5.0 and extracorporeal left ventricular assist device in patients with cardiogenic shock. Int J Artif Organs. 2021;44:846–53.
doi: 10.1177/03913988211040530
pubmed: 34488481
Bergen K, et al. Analysis of bicarbonate-based purge solution in patients with cardiogenic shock supported via Hideki ventricular assist device. Ann Pharmacother. 2023;57:646–52.
doi: 10.1177/10600280221124156
pubmed: 36113415